Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4521 On Other Exchanges
Symbol
Exchange
4521 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

kaken pharmaceutical co ltd (4521) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAKEN PHARMACEUTICAL CO LTD (4521)

Related News

No related news articles were found.

kaken pharmaceutical co ltd (4521) Related Businessweek News

No Related Businessweek News Found

kaken pharmaceutical co ltd (4521) Details

Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. Its pharmaceutical and medical devices products include Artz, an anti-osteoarthritis drug for use in treating knee joint pain accompanied by chronic rheumatoid arthritis; Procylin, which is used to treat chronic artery occlusive diseases and pulmonary hypertension; Adofeed, a pain and inflammation-relieving plaster; Mentax for the treatment of superficial mycosis; Lipidil, an anti-hyperlipidemia product; and Fiblast Spray, a wound-healing product. The company’s pharmaceutical and medical devices products also comprise Ebrantil, a a1 blocker to treat dysuria and hypertension; Berasus for use in treating pulmonary arterial hypertension; Clexane, an anticoagulant for the treatment of patients who undergo podiatric or abdominal surgery under; and Seprafilm, an anti-adhesive absorbent barrier. Its agrochemicals consist of Polyoxins that is used as fungicide; and Pentoxazone, a rice herbicide. The company’s animal health products include Salinomycin, an anti-coccidial feed additive for chicken; and Colistin sulfate, a polypeptide antibiotic effective against gram-negative bacteria. Its products under development include KCB-1D, a Phase-III clinical trial product for the treatment of periodontitis; KAG-308, which is in Phase-I clinical trial for the treatment of Ulcerative colitis; and SI-657 that is in Phase-III clinical trials for the treatment of Enthesopathy. The company also owns and rents bunkyo green court commercial facility. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

Founded in 1917

kaken pharmaceutical co ltd (4521) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kaken pharmaceutical co ltd (4521) Key Developments

Kaken Pharmaceutical Co. Ltd. to Report Fiscal Year 2015 Results on May 12, 2015

Kaken Pharmaceutical Co. Ltd. announced that they will report fiscal year 2015 results on May 12, 2015

Kaken Pharmaceutical Co. Ltd., 2015 Earnings Call, May 13, 2015

Kaken Pharmaceutical Co. Ltd., 2015 Earnings Call, May 13, 2015

Kaken Pharmaceutical Co. Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2014; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2015; Provides Dividend Guidance for the Year Ending March 31, 2015

Kaken Pharmaceutical Co. Ltd. reported consolidated earnings results for the nine months ended December 31, 2014. For the year, the company reported net sales of JPY 71,155 million, operating income of JPY 16,611 million, ordinary income of JPY 16,474 million and net income of JPY 9,605 million or JPY 115.03 per basic share as compared to net sales of JPY 67,018 million, operating income of JPY 11,830 million, ordinary income of JPY 11,621 million and net income of JPY 7,431 million or JPY 86.86 per basic share for the same period a year ago. Income before income taxes and minority interests was JPY 14,728 million compared to JPY 11,602 million a year ago. For the year ending March 31, 2015, the company expects net sales of JPY 91,400 million, operating income of JPY 16,800 million, ordinary income of JPY 16,400 million and net income of JPY 10,700 million or JPY 129.12 per basic share. For the year ending March 31, 2015, the company expects to pay dividend of JPY 27.00 per share compared to JPY 24.00 per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4521:JP ¥4,075.00 JPY -25.00

4521 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4521.
View Industry Companies
 

Industry Analysis

4521

Industry Average

Valuation 4521 Industry Range
Price/Earnings 27.1x
Price/Sales 3.5x
Price/Book 4.2x
Price/Cash Flow 30.8x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAKEN PHARMACEUTICAL CO LTD, please visit www.kaken.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.